PMC5059560_01
(a) H&E section of the diffuse area. (b) CD7 expression in diffuse areas. (c) CD20 expression in diffuse areas. (d) BCL-6 expression in diffuse areas. (e) BCL-6 expression in follicular area. (f) CD7 negative in follicular lymphoma area.
CRIHEM2016-5415974.001.jpg
PMC5059560_01_CRIHEM2016-5415974.001.jpg
fig1
T-cell marker CD3 (Figure 1). These cells coexpressed BCL-2, BCL-6 (Figure 1), and a small subset express MUM-1 and were negative for BCL-1. Follow-up immunohistochemistry also showed CD7 expression but this coexpression was confined to the large cells (specifically the areas involved by the diffuse large B-cell lymphoma) (Figure 1). Notably the areas involved by the follicular lymphoma were negative for CD7 (Figure 1).
Neoplastic cells express CD19 with a subset with expression of CD7. These cells have a high forward scatter, consistent with the CD7 positive large cells.
CRIHEM2016-5415974.002.jpg
PMC5059560_01_CRIHEM2016-5415974.002.jpg
fig2
Interestingly, flow cytometry showed the coexpression of CD7 in a subset of the monotypic B-cells (Figure 2).